Xavier Hernando-Momblona

Xavier Hernando-Momblona

Auto-generated profile, based on publicly available information

Xavier Hernando-Momblona

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2018 in Nature
Verified
Journal Article
Open access
PDF file
Daniele VF TaurielloDaniele VF Tauriello
Daniele VF Tauriello
SPSergio Palomo-Ponce
Sergio Palomo-Ponce
DSDiana Stork
Diana Stork
ABAntoni Berenguer-Llergo
Antoni Berenguer-Llergo
JBJordi Badia-Ramentol
Jordi Badia-Ramentol
EBEduard Batlle
Eduard Batlle
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers1,2. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration3, low type 1 T-helper cell (TH1) activity and reduced immune cytotoxicity2 or increased TGFβ levels4 predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden5, T-cell exclusion3 and TGFβ-activated stroma4,6,7. Inhibition of the PD-1–PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1–PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the TH1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.

23 February 2015 in Nature Genetics
Verified
Journal Article
Closed access
ACAlexandre Calon
Alexandre Calon
ELEnza Lonardo
Enza Lonardo
ABAntoni Berenguer-Llergo
Antoni Berenguer-Llergo
EEElisa Espinet
Elisa Espinet
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle

1 May 2011 in Cell Stem Cell
Verified
Journal Article
Closed access
AMAnna Merlos-Suárez
Anna Merlos-Suárez
FBFrancisco M. Barriga
Francisco M. Barriga
PJPeter Jung
Peter Jung
MIMar Iglesias
Mar Iglesias
MCMaría Virtudes Céspedes
María Virtudes Céspedes
EBEduard Batlle
Eduard Batlle

1 June 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
FBFrancisco M. Barriga
Francisco M. Barriga
EMElisa Montagni
Elisa Montagni
MMMiyeko Mana
Miyeko Mana
MMMaria Mendez-Lago
Maria Mendez-Lago
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
EBEduard Batlle
Eduard Batlle

3 May 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
CCCarme Cortina
Carme Cortina
GTGemma Turon
Gemma Turon
DSDiana Stork
Diana Stork
XHXavier Hernando‐Momblona
Xavier Hernando‐Momblona
MSMarta Sevillano
Marta Sevillano
EBEduard Batlle
Eduard Batlle
The analysis of stem cell hierarchies in human cancers has been hampered by the impossibility of identifying or tracking tumor cell populations in an intact environment. To overcome this limitation, we devised a strategy based on editing the genomes of patient‐derived tumor organoids using CRISPR/Cas9 technology to integrate reporter cassettes at desired marker genes. As proof of concept, we engineered human colorectal cancer (CRC) organoids that carry EGFP and lineage‐tracing cassettes knocked in the LGR5 locus. Analysis of LGR5‐EGFP+ cells isolated from organoid‐derived xenografts demonstrated that these cells express a gene program similar to that of normal intestinal stem cells and that they propagate the disease to recipient mice very efficiently. Lineage‐tracing experiments showed that LGR5+CRC cells self‐renew and generate progeny over long time periods that undergo differentiation toward mucosecreting‐ and absorptive‐like phenotypes. These genetic experiments confirm that human CRCs adopt a hierarchical organization reminiscent of that of the normal colonic epithelium. The strategy described herein may have broad applications to study cell heterogeneity in human tumors. Synopsis To overcome technical and conceptual limitations in the analysis of tumor cell heterogeneity, the genomes of human cancer organoids were edited to integrate reporter and lineage tracing cassettes that enable tracking selected tumor cell populations in vivo. CRISPR/Cas9‐mediated genome editing facilitated the integration of cassettes at marker genes in colorectal cancer (CRC) patient‐derived organoids (PDOs). A GFP reporter integrated at the LGR5 locus labeled a population of ISC‐like tumor cells in human CRCs. The LGR5‐GFP+ cell population was enriched in tumor‐initiating cells. Lineage tracing analysis using CreERT2 knock‐in PDOs demonstrated that in intact tumors LGR5+CRC cells are multipotent, long‐lived and produce cell clones that scale proportional to tumor growth. Double edited LGR5‐GFP/Ki67‐RFP PDOs revealed the existence of proliferating and quiescent LGR5+CRC cells.

22 June 2014 in Nature Cell Biology
Verified
Journal Article
Closed access
GWGavin Whissell
Gavin Whissell
EMElisa Montagni
Elisa Montagni
PMPaola Martinelli
Paola Martinelli
XHXavier Hernando-Momblona
Xavier Hernando-Momblona
MSMarta Sevillano
Marta Sevillano
EBEduard Batlle
Eduard Batlle